Reversal of neuronal and cognitive consequences of amphetamine sensitization following chronic treatment with a D1 antagonist

Neuroplasticity is a key factor in restoration of brain function following neuropathology associated with disease or drug exposure Here we examined the potential for chronic treatment with the selective D1 receptor antagonist SCH39166 to reverse the profound and enduring cognitive impairment associated with amphetamine (AMPH) sensitization in the nonhuman primate and to stimulate re-growth of atrophied pyramidal dendrites in the dorsolateral prefrontal cortex of these animals Four rhesus monkeys with sustained cognitive impairment (>1 year following AMPH sensitization) were treated for up to 8 months with SC1139166 Cognitive testing was performed before, during. and for up to 1 (1)/(2) year following treatment. Significant improvement in working memory performance was observed only after cessation of the D1 antagonist treatment but then was sustained for the duration of the post-treatment testing period. Postmortem quantitative assessment of Golgi-impregnated pyramidal neurons in BA9 showed that apical dendritic length and trunk spine density were increased in D1 antagonist treated monkeys relative to AMPH-sensitized and AMPH-naive monkeys These findings, which suggest that the deleterious consequences of AMPH sensitization can be reversed by modulation of D1 receptor signaling, have implications for treating the underlying neural basis of cognitive deficits in both schizophrenia and substance abuse. (C) 2010 Published by Elsevier Inc